Background While herd effects and serotype replacement by childhood pneumococcal
protein conjugated vaccines (PCVs) continues to accumulate worldwide, direct effectiveness …

Background There is no one-size-fits-all empiric antimicrobial therapy for sepsis because
the pathogens vary according to the site of infection and have changed over time. Therefore …

Background In the randomized controlled Community-Acquired Pneumonia Immunization
Trial in Adults (CAPiTA), the efficacy of the 13-valent pneumococcal conjugate vaccine …

Introduction Community-acquired pneumonia (CAP) is a common infection associated with
high morbimortality and a highly deleterious impact on patients' quality of life and …

Background The objective of this study is to evaluate rates of all-cause pneumonia among
“at-risk” and “high-risk” children and adults in Germany—in comparison with age-stratified …

Background The impact of pneumococcal conjugate vaccination on the prevalence of
nasopharyngeal carriage with pneumococci and other bacteria in adults is unknown. The …

RESUMO A pneumonia adquirida na comunidade (PAC) constitui a principal causa de
morte no mundo. Apesar da vasta microbiota respiratória, o Streptococcus pneumoniae …

В обзоре рассматриваются клинические и эпидемиологические связи между COVID-19
и пневмониями. При этом обсуждаются как общие закономерности, связывающие …

Community-acquired pneumonia (CAP) is the leading cause of death worldwide. Despite
the vast diversity of respiratory microbiota, Streptococcus pneumoniae remains the most …

Abstract Background Since 2014, Belgium's Superior Health Council has recommended
pneumococcal vaccination for adults aged 19–85 years at increased risk for pneumococcal …